Investor Presentation March 2023

GAAP to Adjusted EBITDA Reconciliation for the three months ended December 31, 2022 and 2021 (in $ thousands) Three Months Ended December 31, 2022 2021 $ (86,932) $ (83,411) GAAP Consolidated net loss Adjustments (a): Interest expense Income tax benefit Depreciation and amortization Stock compensation expense (1) Acquisition and integration costs (2) Startup costs Restructuring costs (3) Unrealized foreign exchange gain Loss on debt extinguishment Amortization of inventory step up 10,450 4,828 (15,974) (12,785) 13,263 6,024 2,046 23,932 983 8,808 1,505 957 266 1,250 320 877 244 3,668 Loss (gain) on disposition of assets 380 (249) Loss on fair value remeasurement of convertible notes (4) Other non-recurring, third party costs Goodwill impairment loss (5) Adjusted EBITDA (b) $ 671 66,367 (5,481) $ 10,122 56,714 439 (a) Adjustments to certain GAAP reported measures for the three months ended December 31, 2022 and 2021 include, but are not limited to, the following: (1) (2) (b) (3) (4) For the three months ended December 31, 2021, $23.0 million relates to post combination non-cash stock compensation expense relating to the adoption of the Envigo Equity Plan recognized in connection with the Envigo acquisition. For the three months ended December 31, 2021, represents charges for legal services, accounting services, travel and other related activities in connection with the acquisition and integration of Plato BioPharma, Envigo and RSI. For the three months ended December 31, 2022, represent charges for legal services, accounting services and other related activities in connection with the acquisitions of Plato BioPharma, Envigo, RSI, ILS, OBRC, Histion and Protypia. For the three months ended December 31, 2022, represents costs incurred in connection with the exit of our Dublin and Cumberland sites. For the three months ended December 31, 2021, represents loss of $56.7 resulting from the fair value remeasurement of the embedded derivative component of the convertible notes. (5) For the three months ended December 31, 2022, represents a non-cash goodwill impairment charge of $66.4 million related to the RMS segment. Adjusted EBITDA - Consolidated net (loss) income before interest expense, income tax expense (benefit), depreciation and amortization, stock compensation expense, acquisition and integration costs, startup costs, restructuring costs, unrealized foreign exchange loss, loss on debt extinguishment, amortization of inventory step up, gain/loss on disposition of assets, loss on fair value remeasurement of the embedded derivative component of the convertible notes, other non-recurring third party costs and goodwill impairment loss. 29

View entire presentation